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Abstract
Human genetics recently transitioned from GWAS to studies based on NGS data. For GWAS,
small effects dictated large sample sizes, typically made possible through meta-analysis by
exchanging summary statistics across consortia. NGS studies groupwise-test for association of
multiple potentially-causal alleles along each gene. They are subject to similar power constraints
and therefore likely to resort to meta-analysis as well. The problem arises when considering
privacy of the genetic information during the data-exchange process. Many scoring schemes for
NGS association rely on the frequency of each variant thus requiring the exchange of identity of
the sequenced variant. As such variants are often rare, potentially revealing the identity of their
carriers and jeopardizing privacy. We have thus developed MetaSeq, a protocol for meta-analysis
of genome-wide sequencing data by multiple collaborating parties, scoring association for rare
variants pooled per gene across all parties. We tackle the challenge of tallying frequency counts of
rare, sequenced alleles, for meta-analysis of sequencing data without disclosing the allele identity
and counts, thereby protecting sample identity. This apparent paradoxical exchange of information
is achieved through cryptographic means. The key idea is that parties encrypt identity of genes and
variants. When they transfer information about frequency counts in cases and controls, the
exchanged data does not convey the identity of a mutation and therefore does not expose carrier
identity. The exchange relies on a 3rd party, trusted to follow the protocol although not trusted to
learn about the raw data. We show applicability of this method to publicly available exome-
sequencing data from multiple studies, simulating phenotypic information for powerful meta-
analysis. The MetaSeq software is publicly available as open source.
1. Introduction
Human genetics has recently undergone a transition from genomewide association studies
(GWAS) based on genotyping common polymorphisms1–4 to studies based on next
generation sequencing (NGS) data5–7, that ascertains common and rare variants across
individuals8. For GWAS, low effect sizes of most of the causal common alleles on common
diseases and quantitative traits dictated large sample sizes to achieve statistical power9. In
many studies, such sizes were made possible by consortia of multiple collaborating groups,
each contributing hundreds or thousands of samples, together amassing tens or hundreds of
thousands of genotyped samples to detect minute effects on various phenotypes10.
Computational methods for meta-analysis of such collated GWAS datasets have been
instrumental in facilitating their joint analysis11.
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NGS studies met initial success using only a handful of samples for sequencing exomes12,13
or whole genomes14,15 to detect novel, fully-penetrant alleles that disrupt genes and cause
disease. Yet, detecting disease genes with rare alleles of partial penetrance, that explain only
a small fraction of the cases, is more challenging. First, the limited power to detect such
alleles on their own motivates testing for association of multiple alleles along the gene 16.
Indeed, multiple methods for groupwise testing of alleles have been developed to optimize
power of detecting such multiply disrupted genes17–22. Second, the tautological problem
with rare variants is their low frequency. Large numbers of samples are still required in
order to observe such alleles and detect their significant association. Fortunately, the cost of
NGS keeps dropping, and the throughput keeps increasing. Sequencing exomes now require
reagent-cost and labor resources comparable to early GWAS, with genomes likely to soon
follow. This paper is motivated by the assumption that these power constraints along with
throughput opportunities will lead to large-scale disease sequencing studies23 that would be
more rapidly, and therefore more competitively executed by groups operating in parallel, but
jointly meta-analyzing their data.
Privacy had been a thorny issue in genetics research24–26. The irreversible labeling of
individuals if their genetic information is known requires broad consent by study
participants in order for researchers to have the ethical right and legal permit to expose their
genotype data or even to share it with peers and collaborators27,28. This, along with some
investigators’ sense of ownership of their data and cohorts typically makes data-access in
human genetics (unlike other fields29,30) restricted, at least initially, often to the investigator.
In GWAS, large consortia had preserved such access restriction, as meta-analysis required
only exchange of summary statistics across collaborating groups and institutional barriers,
rather than sharing explicit genotype data31. Such summary statistics typically include
essentially allele frequencies (and their confidence levels) per marker. Although formally
individuals and their relatives can be identified as members of a cohort just based on these
summary statistics32, this identification requires expert computation, and may be
underpowered, depending on study parameters such as number of SNPs, sample size and
allele frequencies33.
Meta-analysis of sequencing data poses unique challenges in terms of subject privacy.
Specifically, such data includes hundreds of thousands of rare alleles per genome34, among
them de novo mutations35, one or two of which can uniquely identify an individual among
the entire world population. Even exome sequences typically include thousands of alleles
that are currently novel13. Even assuming future expansion of variant databases, a typical
human exome will have thousands of very rare (frequency < 10−4) alleles, typically
singletons within a cohort of size in the low thousands. Such alleles, alone or in concert,
readily provide unambiguous identification of carrier of the sample. The classical summary
statistic for meta-analysis, which is the list of allele frequencies in a sample, therefore
provides clear indication of membership for each and every sample in the cohort if applied
genomewide with the exception of monozygotic twins, simply by virtue of including the
singleton alleles carried by this sample. A similar rationale would decide or rule out
membership in an exome-sequenced cohort based on presence of rare mutations. Yet, allele
frequencies in cases and controls across the entire set of analyzed samples are a key
ingredient in multiple methods for association to rare alleles18,19,21. Exchange of allele
frequencies between consortium members in order to tally alleles across datasets is
instrumental for meta-analysis of sequencing data, posing an apparent conflict with ethical
requirements to protect against identification of samples.
This paper tackles the challenge of facilitating the tally of frequency counts of rare,
sequenced alleles between consortium members, thus enabling meta-analysis of sequencing
data while not disclosing the allele identity and counts, therefore providing considerable
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protection of sample identity. This apparent paradoxical exchange of information is
achieved through cryptographic means. The key idea is that parties hide the identity of the
variants. When they transfer information about frequency counts in cases and controls, it
does not convey the identity of a mutation, therefore not exposing the identity of the carriers.
The parties do use an identical encryption key, thus identical variants will be encrypted
identically. One could therefore sum up the counts for identical variants, without knowing
the identity of the alleles whose counts are being tallied.
2. Methods
2.1. Notation
We hereby describe MetaSeq, a privacy preserving protocol for meta-analysis of sequencing
data coming from C collaborators such that:
• Each collaborator c has data on a set S[c] of samples.
• Such data includes a set Vm[c] of positions along each gene gm among the M ~
20,000 genes g1, g2 … gM. Vm[c] specifies all positions where variant (no-
reference) calls had been made for at least one sequenced individual i ∈ S[c].
• The data further includes for each individual i ∈ S[c], and each variant position v ∈
Vm[c] the actual genotype of i at v: heterozygote or non-reference homozygote,
denoted by hm[c](v,i), represented in a standard vcf format36. We define Hm[c] to
be full matrix of genotype values, across all rows v ∈ Vm[c], and columns i ∈ S[c].
Effectively, Hm[c] is a matrix of values 0,1, or 2 for each position and individual.
• For each individual i ∈ S[c], the data also includes the affection status or the
phenotype value of i, denoted by p(i) ∈ {1,0} for cases and controls, respectively.
We denote P[c] as the list of phenotype values p(i) for each i ∈ S[c].
We assume Vm[c] is listed as genomic coordinates: chromosome and position along the
chromosome. For each such position x, we define the coordinate, ϕm(x), which is its offset
from the start of the chromosome. We naturally extend ϕm(.) to operate on sets of positions.
In practice we assume ϕm(x) is a 32-bit integer.
We define the set of all variable positions along the chromosome for gene, gm, and the total
set of individuals respectively, as follows:
(1)
(2)
We further define the full listing P of phenotype values for all individuals across all cohorts
and the full set G of genes, g1 .. gM | M ~ 20000. Hm is defined as the genotype matrix
across all cohorts, with columns for all i ∈ S, and rows for all v ∈ Vm. Hm[c] is the minor of
Hm induced on Vm[c]×S[c]. The data for gene m is Dm = {Vm, Hm}, and the entire genetic
dataset is given as:
(3)
2.1.1. Association score—Let F(Dm =(Vm,Hm), P) be the scoring function used for
testing association of gm. We assume F has certain properties that are shared by standard
methods for testing association18.
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Specifically, F remains fixed when swapping rows (variants) of Hm along with Vm, if we
assume all variants considered by the test are similarly likely to be causal (this assumption
can be relaxed). Also, the set of scores for all genes by definition remains fixed when
swapping genes gm.
(4)
The goal of the protocol is to encrypt the data using a secret key k, such that gene labels and
variant labels are swapped (or permuted). Specifically, we define key-dependent
permutations gk and ρk on gene labels and potential coordinates (32-bit integers),
respectively. The permuted data for each gene is denoted by the following equations:
(5)
(6)
where, ρk(Vm) is the set of permuted coordinates and ρk(Hm) is the matrix of genotype calls
with permuted rows, i.e., with values hm[ρk(ϕm(v)),i]for all v ∈ Vm, i ∈ S. We observe that
the score is unchanged by this transformation: F(ρk(Dm),P) = F(Dm,P). Yet, if one were to
observe only a minor of ρk(Dm), corresponding to a subset of individuals and the
corresponding subsets of variants that they carry, one does not obtain any information on the
individuals not in this subset, nor on the variants not carried by these individuals.
Specifically, for each cohort c, the relevant subset of the data, Dm[c] = (Vm[c], Hm[c]), when
encrypted into ρk(Dm)[c], does not provide information regarding any other cohort c′ ≠ c,
nor on any variants not in Vm[c]. In this sense, the encryption is privacy preserving. Finally,
if gene labels are permuted, then receiver of the permuted data Dg(k ) = {Dgm(k ) |m ∈ 1..M}
cannot learn anything about the identity of any gene.
We have developed a 5-step protocol for meta-analysis of genomewide sequencing data,
computing association scores for pooled rare variants. The protocol is presented here in
simplified form, with the following leniencies:
1. We discuss only two-way meta-analysis, where two investigators (collaborators),
Alice and Bob (or c1 and c2), each have their own sequenced association cohorts.
2. We consider case-control association testing.
3. We present the calculation of a simple variable allele-frequency threshold score21.
4. Alice and Bob rely on the assistance of a semi-trusted third party, Trent, to help
compute the score.
The protocol preserves privacy of the subjects in the following respects:
1. The only information Alice and Bob learn about each other’s cohort is the scores of
top-associated genes.
2. Trent does not have direct or practical information that could expose the identity of
the subject in Alice and Bob’s cohorts. Specifically, Trent does not learn which
genes harbor which mutations in each cohort, and given an exome of an individual,
cannot determine whether that individual is a member of any of the cohorts. Even
upon publication of the research results by Alice and Bob, the information that
Trent learns, is limited.
2.1.2. Protocol—The protocol proceeds as follows:
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Alice and Bob choose a shared secret key k, that can serve as an encryption key
2. Annotation and Encryption:
Alice and Bob each encrypt their data as follows:
a. Variants are annotated for the genes they belong to and variant
classification, e.g. known or nonsense, needed for scoring. Such
classification is kept unencrypted.
b. Alice and Bob generate a secret permutation g(k) over the set of genes
g1…gM, creating permuted gene identifiers, g1(k)…gM(k).
c. They further secretly permute the set of variants Vm, creating Vm(k).
3. Data Transfer:
Alice and Bob send Trent their encrypted gene names g1(k)…gM(k) and variant
positions, Vm(k) along with the (unencrypted) (frequency) counts fVm(k)[ci].
4. Merging and association testing:
Trent computes, for each (permuted) gene gm(k) a total count for each (encrypted)
variant, Vm(k) by summing the two counts fVm(k)[c1] and fVm(k)[c2] if both Alice
and Bob report the variant in gm(k) or collapsing the association score for the
variants otherwise.
5. Decrypt results:
Trent sends Alice and Bob the (top) association scores assigned to specific
(encrypted) gene names, that they are able to decrypt.
Note that many rare-variant association tests focus on particular type of variants, e.g. non-
synonymous, or loss-of-function variants. Such information is lost upon encryption, and
Trent will thus be unable to restrict analysis to a particular class of variants. A convenient
workaround is to communicate a set of per-variant weights by both Alice and Bob. Weights
depend on classification of variant type that is agreed upon in advance, i.e. Alice and Bob
decide on a weight function W:T→[0,1] on the domain of all variant types T = {missense,
synonymous coding …..}. Each variant v is assigned type t(v) ∈ T and therefore a real-
valued weight W(t(v)) ∈ [0,1], is communicated to Trent in clear text. We make note of the
fact that since both gene names and variant positions are encrypted, for a sufficiently large
class of variant types it becomes difficult for Trent to make any concrete inferences on
variant identities using this information.
2.1.3. Implementation: MetaSeq—We implemented this protocol as MetaSeq, an open
source PERL package. A step-by-step illustration of the protocol as is in the MetaSeq code
is given in Figure 1. We assume that the collaborators have their data stored on a server that
is remotely accessible using the server name. We also require tools for annotation and
encryption of the data on the server. MetaSeq works on variant call files (*.vcf format) that
include genotypes and phenotypes for each collaborating party, and is available as open
source at https://github.com/angadps/Rare-Variant-Association.
We provide implementation details regarding specific steps of MetaSeq:
Step 1: Registration & key exchange: MetaSeq guides the collaborating parties through
the key exchange procedure using the PERL encryption modules Crypt::DES37,
Crypt::CFB38 and Crypt::CBC39, and allows an arbitrary number of collaborators, instead of
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just the pair of Alice and Bob. In detail, the collaborators register with Trent using their
server names. Communication between the servers is via the use of sockets. A specific port
is designated on the servers for all data exchange and communication between the servers.
Trent signals the key generation process after registration. All collaborators contribute a
seed towards the generation of the key, of which Trent has no information about or
contributes in any way towards the generation of either. We use the MD5 algorithm to
generate a 32-bit key.
Step 2: Annotation & encryption: Each party then encrypts the data, which are first
annotated by the vcfCodingSnps tool40 on a per gene basis. The purpose of annotation is
two-fold. Firstly, it helps us prepare the genotype and phenotype files separately for every
gene as required by the association test. Secondly, it helps us in restricting the analysis to
certain class of variants, or in assigning different weights to different classes. For that
purpose, additional input to MetaSeq is a file of weights that needs to be agreed upon in
advance. Variant data is encrypted per the protocol, and communicated as numeric 32-bit
dumps – sufficient to uniquely index positions along any chromosome. At the same time we
would like to point out that we have tested MetaSeq to work with gene level annotations
only, although the idea could be extended to any general definitions of region for
annotations as long as it is consistent across studies.
Step 4: Merging and association testing: MetaSeq is implemented with the Variance
Threshold (VT) test21 of association, but can in principle include other tests as well. The
encrypted files received by Trent from Alice and Bob are first merged by their (encrypted)
gene names. This prepares the data from all collaborators for the pooled association test.
2.2. Simulation Testing
We used simulation to evaluate the power of meta-analysis assuming different numbers of
causal variants in a single gene. Power here is defined as the fraction of successful
association tests. Specifically, for each such number, we simulated 100 datasets of 50 cases
and 50 controls collected by each of C=10 collaborators. We tested association by each
single-collaborator vs. pooled across collaborators in a privacy-preserving manner. We
tallied the fraction of successful association tests, but note that reporting a success requires
more care in this study than usual. In detail, a conservative definition of success is when the
true gene is the unique top-scoring gene (for either single-collaborator or pooled testing
modes). A more lenient definition allows other top-scoring genes to tie with the true gene
(again, for both modes). Finally, without privacy-preserving data analysis, one can consider
independent PIs running the association test, and then decide about the associated gene
based on the individual results of all of them, by taking a majority vote. We report power
based on each of these 5 modes of analysis. We repeated this for 1,2,22, … 210 causal
variants for the causal gene, in addition to 1000 neutral variants for each gene. We simulated
the case and control sequencing data using an implementation of the Wright-Fisher model41,
that allows setting particular numbers of causal and neutral variants. The Wright-Fisher
Model gives the probability density function f(p), of the probability of encountering a
mutation, p as follows:
(7)
Here, f(p) is the probability function of the mutation-probability p, bs is the scaled mutation
rate of disease mutations, bn is the scaled back-mutation rate, s is the scaled selection rate
and c is the constant that normalizes the integral of f(p) to 1.
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3.1. Power of pooled-collaborators vs. single-PI testing
We report results from all the variants of the power tests stated above. Plots for the same are
shown in Figure 2. Throughout the range of parameters, pooled tests are better powered
compared to single-PI tests. This advantage is most pronounced when there are only few
causal variants along the truly causal gene. At the extreme, 1–8 causal variants in a gene, we
observe decently powered pooled test (up to 55% power for the conservative test) compared
to a severely (<5%) underpowered single-PI test, an improvement of up to 50 percentage
points or 10 – 30 times with the pooled tests. Naturally, lenient reporting of success enjoys
higher power, but would potentially require following up multiple promising genes, rather
than only one.
We note that the number of causal, case-only variants is a natural parameter here – the rare-
allele analog of the size of effect to be detected. Power is further influenced by nuisance
parameters, such as the span of a gene in basepairs (hence, the number of neutral variants
along it, here normalized to be 1,000), and the genetic length of a gene in centimorgans
(hence, the effective number of independent variants along it). This explains some of the
genes being hard to find as associated, even with many rare case-only variants simulated.
Potential false positives or false negatives in the context of meta-analysis alone are expected
to be minimal (otherwise, the same concerns may apply as in the case of single cohort tests).
Since variant frequencies are collapsed across all cohorts and for all variants in a gene, such
loss of data, which is the primary input for the protocol is not expected. Also, encryption is
performed in a loss-less manner i.e., no genes or variant ids are expected to be lost in the due
course of execution of the protocol.
3.2. MetaSeq requirements of computing resources
We state the time and space requirements for MetaSeq in Table 1. The tests were run on a
Sun Grid Engine controlled cluster with sufficient number of compute cores and maximum
8GB of RAM given to a single test at any time. We state the time and space that was
required for a single run of MetaSeq with 1000 neutral variants per gene, broken down by
small steps of the protocol. Some of the steps, i.e., registration, key generation, transfer of
results, and decryption are insignificant both in terms of time and space. Yet, these steps are
reported here for completion. In total, MetaSeq can be completed in 3.5 hours of elapsed
time using less than 30 hours of CPU resources, using at its peak 150MB of space in total.
Network footprint is even smaller, as transmitted files are archived and zipped. The most
intensive parts in terms of computing resources are the annotation and encryption stages that
need to I/O information in 200,000 files (one per gene per collaborator). The most CPU is
used during association testing, for permuting the data 100,000 times to assess significance.
We parallelize this stage over 20 cores.
4. Discussion
We developed MetaSeq, a protocol that relies on a trusted third-party to compute the
association scores over the intersection of the variant set. We implemented the protocol in
PERL and have made it available as an open source package. Our protocol is designed to be
robust in securing private genetic information, while at the same time making only minimal
assumptions about compliance of the parties to the protocol.
In securing private genetic information, we try to preserve privacy against participating
collaborators knowing individual-level identifying information, such as private mutations.
This is achieved by computing an association score, not by one of the parties, but rather by a
designated third-party, who also needs to stay in the dark and not learn the identity of the
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study participants and their private mutations. The third-party, after collating data and
performing the desired computations, is assumed to follow protocol, and not to share variant
information with any of the collaborators. The third-party is considered to be “trusted” in
this regard. At the same time we need to secure information from the third-party as well. We
achieve this by this party only working with encrypted data, never having access to the
secret key that was used to encrypt all the genetic information. Hence, while the third-party
has access to all the data, it is still meaningless to that party, since the data is in encrypted
form and the encryption key is not available to it.
We make the assumption that no collaborator conspires with the third-party to share the key,
as that would violate the desired privacy requirements. Another potential breach that can
arise is when more than one collaborator plan to collate their datasets so as to draw
inferences regarding the data from the remaining collaborators. However, such estimations
can only be effectively made only if all but one of the collaborators get together and
conspire against the remaining one. Even then, the coalition would, at best, learn limited
information about the cohort of the conspired-upon collaborator, e.g., presence of variants
that they already have in their cohort. The coalition will not learn the identity of private
variants.
Another way that collaborators can violate protocol to learn the alleles is to send
monomorphic data to the third-party for their own dataset. In this way they are sure that any
identified carrier alleles are coming only from the datasets of other collaborators. This is
possible only if all but one of the collaborators is sending monomorphic data, and we
assume the parties follow protocol. At the same time it is assumed that there may be
(approximately) a minimum of 5 collaborators in any run of the protocol. Under this
assumption it is difficult for a single collaborator to learn the datasets of any other single
collaborator by employing such mechanisms.
Finally, a collaborator may try to estimate datasets by computing a prior distribution of the
results obtained from the final computation of scores, which is OK, and then use their own
dataset to obtain a better posterior distribution. However, they only have a chance to learn
about variants that are shared, rather than private to a cohort, and only within the top-scoring
genes. A theoretical analysis of the privacy guarantees of the protocol may resemble the one
by Sankararaman42 to some extent although we are now working in the MAF < 0.5 range. A
complete analysis however remains out of scope for this paper and will be considered for
future work.
Privacy preserving protocols of this sort have been investigated in the cryptography
literature as secure multiparty computation43. Over the last decade, protocols have been
proposed for joint computation of the intersection of two or more subsets44 that can be
employed to compute the intersection of the variant set. More generally, theoretical results
guarantee the ability to simulate any privacy-preserving protocol that uses a third trusted
party without the need of such a party45. Similar to meta-analysis techniques in GWAS, the
application of similar techniques for NGS studies is expected to reveal the role of many rare
variants in Mendelian diseases.
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Flow diagram of MetaSeq: Two Investigators, Alice and Bob compute per-gene scores on
their pooled data without revealing the data to one another nor to a third party, Trent, who
computes association scores “blindfolded”. The figure describes a simple scenario using
three genes, one of which, including a single variant in it, is common to Alice and Bob. The
gene name and variant position for this is encrypted to the same text, thus being merged
together by the 3rd party before association testing. This gene scores higher compared to
other genes, as shown in the results decrypted by individual collaborators on their servers.
Note that the generation of the key to be used for encryption is coordinated between Alice
and Bob, excluding Trent in the process. Also note that while the figure does not point out
phenotype information explicitly, the association testing step of the protocol receives the
frequency data segregated for case and control cohorts, respectively.
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Log-scaled power plot for pooled and single-PI tests. Results are plotted for all three
definitions of success (unique and non-unique causal gene for pooled and single-PI tests,
majority vote for single-PI tests only). In the unique and non-unique gene plots for the
single-PI tests, the final success rate is calculated by averaging the number of successes
across all PIs per dataset. In the majority vote plot, a majority vote of the number of
successes is taken per single-PI per dataset. The different nature of success here explains the
region in the figure where the plot for single-PI unique gene tests is higher than the majority
vote plot.
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Table 1
Space and time requirements of MetaSeq. The benchmark runs included 10 collaborators, with each one
contributing 100 samples to the pooled analysis including 1000 neutral variants per gene. Runs include all
~20,000 genes along the genome. Steps performed by the collaborating parties (“Alice & Bob”, though in this
benchmark also 8 other collaborators) are evaluated for resources required per party. Also time taken for the
association test mentioned is with a parallelism of 20. A total of 20 CPU hours were effectively needed for the
association testing, although total memory required is less than 1MB. Note that decryption takes negligible
time as opposed to encryption since the parties only need to decrypt the list of top-scoring gene names.




1.2 Generate key Nil Nil Nil
2.1 Annotate 18 180 15
2.2 Encrypt 27 270 12




4.2 Test association 60 1200 1
5.1 Transfer results Nil Nil Nil
5.2 Decrypt Alice & Bob Nil Nil Nil
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